SimcoDerm Medical & Surgical Dermatology Centre is proud to announce a major milestone in our clinical research program: we are the first clinical trial site worldwide to randomize a patient into the CYTRIL clinical trial for Hidradenitis Suppurativa (HS).

This achievement reflects:

Leading Operational Excellence

Our clinical trials unit has built a reputation for rapid start-up, rigorous protocol adherence, and exceptional recruitment capacity. Being the first site globally to randomize a patient underscores the efficiency and precision of our internal systems, investigator oversight, and coordinator expertise.

Commitment to Advancing HS Research

Hidradenitis Suppurativa remains an under-recognized, highly debilitating disease with limited effective treatment options. Early participation in novel therapeutic development is a critical step toward improving care and providing hope to patients living with HS.

A Dedicated, Multidisciplinary Team

This milestone was made possible by the exceptional work of our dermatologists, clinical research coordinators, nurses, and support staff. Their commitment allowed us to meet all regulatory, training, and operational requirements ahead of schedule and to identify and screen eligible patients swiftly and carefully.

Strengthening Canada’s Leadership in Dermatology Research

Being the first global site to randomize in the CYTRIL trial highlights Canada’s growing prominence in dermatology innovation. At SimcoDerm, we remain dedicated to expanding access to cutting-edge therapies for our patients and contributing meaningful data to global research initiatives.